Data gathered: January 13
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated January 2, 2025. Powered by Chat GPT.
X4 Pharmaceuticals is a biotechnology company that focuses on the development and commercialization of novel therapeutics. Their primary goal is to address significant unmet medical needs in the realm of rare disorders. The company's approach leverages its deep expertise in small molecule drug discovery, along with a proprietary pipeline of innovative candidates aimed to deliver breakthrough treatments for patients with rare diseases.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | January 10 Price is down by -5.7% in the last 24h. |
|
X4 Pharmaceuticals | January 8 Price is down by -5.7% in the last 24h. |
|
X4 Pharmaceuticals | January 7 Price is down by -5.1% in the last 24h. |
|
X4 Pharmaceuticals | January 6 Price is down by -5.1% in the last 24h. |
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 14 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,067 | Sign up | Sign up | Sign up |
| Twitter Followers | 995 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 137 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $0.57 |
| Target Price | Sign up |
| Volume | 1,610,000 |
| Market Cap | $97M |
| Year Range | $0.28 - $1.11 |
| Dividend Yield | 0% |
| PE Ratio | 2.85 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Brookline Capital Management Predicts XFOR FY2024 EarningsJanuary 10 - ETF Daily News |
|
Geode Capital Management LLC Lowers Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)January 8 - ETF Daily News |
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Bought by State Street CorpJanuary 2 - ETF Daily News |
|
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Bought by XTX Topco LtdDecember 22 - ETF Daily News |
|
Point72 Asset Management L.P. Boosts Stock Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)December 13 - ETF Daily News |
|
X4 Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XFOR)December 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | 0.000 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | 93M | -0.070 |
| Q1 '24 | 0 | 0 | -19M | -52M | -37M | -0.260 |
| Q4 '23 | 24M | 9.9M | -12M | -19M | -25M | -0.100 |
| Q3 '23 | 0 | 0 | -9.7M | -2.3M | -26M | -0.010 |
Insider Transactions View All
| Ragan Paula filed to sell 993,919 shares at $0.4. November 19 '24 |
| Ragan Paula filed to sell 1,025,816 shares at $0.6. October 16 '24 |
| Taveras Arthur filed to sell 388,026 shares at $0.6. October 8 '24 |
| DiBiase Mary filed to sell 452,060 shares at $0.6. October 8 '24 |
| Baldry Mark filed to sell 48,509 shares at $0.6. October 8 '24 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $97M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 2.85.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $0.57.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.